BioMarin (BMRN) Files NDA for Vosoritide to Treat Dwarfism

BioMarin Pharmaceutical Inc. BMRN filed a new drug application (NDA) for vosoritide to the FDA to treat children with achondroplasia, the most common form of dwarfism for which no drug is approved yet.